Fresenius stock gains support as UBS and JP Morgan reiterate buy calls

Fresenius SE & Co. KGaA stock (ISIN DE0005785604) is trading firmly supported, with the Xetra listing closing at 44.68 euros on September 8, 2026 and backed by fresh buy ratings from UBS and JP Morgan. As The Globe and Mail reported on September 9, 2026, UBS maintained its Buy rating with a price target of 56.00 euros, while the average analyst target of 55.28 euros implies upside of around one quarter from the current level.

Analysts see upside after Q2 2026 beat

According to Zonebourse, Fresenius published its results for the second quarter and first half of 2026 for the period ended June 30, 2026, delivering revenue of 5,864 million euros in Q2 2026 versus a consensus expectation of 5,837 million euros, a positive variance of 0.46 percent. The same overview shows that revenue in Q1 2026 came in at 5,819 million euros compared with a forecast of 5,786 million euros, a beat of 0.58 percent, illustrating a pattern of slightly better-than-expected top-line performance over consecutive quarters. For investors, the fact that Q4 2025 revenue of 5,961 million euros was almost exactly in line with the 5,958-million-euro forecast, a deviation of just 0.05 percent, underscores a track record of delivering close to guidance with modest positive surprises.

The Q2 2026 release was accompanied by an increase in the company’s full-year 2026 objectives after results came in above expectations, as highlighted by Zonebourse in its summary dated August 5, 2026. That guidance upgrade acts as an important backdrop for the latest analyst actions, as higher revenue and earnings targets typically support more constructive valuation views. With Q2 2026 revenue slightly ahead of forecasts and guidance raised, the market narrative has shifted towards Fresenius as a steady grower rather than a recovery story only.

UBS and JP Morgan reiterate buy stance

As The Globe and Mail reported on September 9, 2026, UBS analyst Graham Doyle reaffirmed a Buy rating on Fresenius with a price target of 56.00 euros, citing the company’s fundamentals and outlook. The same report notes that the average analyst price target stands at 55.28 euros, with the shares having a one-year high of 52.96 euros and a one-year low of 35.11 euros, indicating that the current price is below the consensus target but not far from the recent peak. The spread between the 44.68-euro Xetra close on September 8, 2026 and the 56.00-euro UBS target represents potential appreciation of roughly 25 percent if the valuation scenario materializes.

JP Morgan has also taken a positive stance recently. According to Zonebourse on September 9, 2026, analyst Anchal Verma at JP Morgan continues to recommend buying the stock, keeping an overall positive view. The same Tradegate-based snapshot shows a real-time estimated price of 44.34 euros with a five-day performance slightly negative and a year-to-date decline of 8.77 percent, underlining that the buy recommendations come despite the share price still trading below its one-year high. For retail investors, the combination of a Strong Buy consensus and a double-digit gap to average targets is a key part of the equity story.

International listing and recent price performance

Beyond the German listing, Fresenius also trades in the United States via the FSNUY American depositary receipt on OTC Markets. Price data from Zonebourse show that FSNUY closed at 12.97 US dollars on OTC Markets at 9:59 p.m. on September 8, 2026, a daily gain of 1.97 percent, while the year-to-date performance stood at minus 9.49 percent at that time. Over the most recent five trading days in early September 2026, the ADR fluctuated between 12.72 and 12.98 US dollars, with daily moves ranging from a loss of 1.85 percent to small negative changes around 0.04 percent, illustrating a relatively tight trading range despite the longer-term negative year-to-date trend.

The same data set indicates that FSNUY has an average volume of about 1.18 million US dollars at the current price levels, reflecting meaningful liquidity for US-based investors accessing Fresenius through the OTC route. In combination with the Xetra closing level of 44.68 euros on September 8, 2026 highlighted by Zonebourse, the ADR pricing implies a stable ratio between the euro and US dollar quotations. For investors comparing venues, the primary reference remains Xetra in euros, while the ADR offers a convenient alternative in dollars.

Stock price level and upcoming dates

At 44.68 euros on Xetra as of September 8, 2026, Fresenius stock trades meaningfully above its one-year low of 35.11 euros yet still below the one-year high of 52.96 euros reported by The Globe and Mail, placing the shares roughly in the middle of their recent trading range. According to the financial calendar on Zonebourse, Fresenius scheduled the publication of its Q4 2026 results and a related presentation for August 8, 2026, alongside an information meeting, while Q2 2026 results were published on August 5 and August 31, 2026 depending on venue. Looking forward, the same agenda lists an extraordinary general meeting on September 3, 2026 and a dividend detachment of 0.20 US dollars per share on September 1, 2026, events that frame the company’s capital-market activity around the latest reporting season.

More news and analyses on Fresenius stock